Born to survive: how cancer cells resist CAR T cell therapy

Abstract Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean Lemoine, Marco Ruella, Roch Houot
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Immunotherapy Lymphoma Leukemia Myeloma Therapy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/160e195e48c640ac9e65ed6f10b77e15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:160e195e48c640ac9e65ed6f10b77e15
record_format	dspace
spelling	oai:doaj.org-article:160e195e48c640ac9e65ed6f10b77e152021-11-28T12:03:21ZBorn to survive: how cancer cells resist CAR T cell therapy10.1186/s13045-021-01209-91756-8722https://doaj.org/article/160e195e48c640ac9e65ed6f10b77e152021-11-01T00:00:00Zhttps://doi.org/10.1186/s13045-021-01209-9https://doaj.org/toc/1756-8722Abstract Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.Jean LemoineMarco RuellaRoch HouotBMCarticleImmunotherapyLymphomaLeukemiaMyelomaTherapyDiseases of the blood and blood-forming organsRC633-647.5Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunotherapy Lymphoma Leukemia Myeloma Therapy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunotherapy Lymphoma Leukemia Myeloma Therapy Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jean Lemoine Marco Ruella Roch Houot Born to survive: how cancer cells resist CAR T cell therapy
description	Abstract Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.
format	article
author	Jean Lemoine Marco Ruella Roch Houot
author_facet	Jean Lemoine Marco Ruella Roch Houot
author_sort	Jean Lemoine
title	Born to survive: how cancer cells resist CAR T cell therapy
title_short	Born to survive: how cancer cells resist CAR T cell therapy
title_full	Born to survive: how cancer cells resist CAR T cell therapy
title_fullStr	Born to survive: how cancer cells resist CAR T cell therapy
title_full_unstemmed	Born to survive: how cancer cells resist CAR T cell therapy
title_sort	born to survive: how cancer cells resist car t cell therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/160e195e48c640ac9e65ed6f10b77e15
work_keys_str_mv	AT jeanlemoine borntosurvivehowcancercellsresistcartcelltherapy AT marcoruella borntosurvivehowcancercellsresistcartcelltherapy AT rochhouot borntosurvivehowcancercellsresistcartcelltherapy
_version_	1718408242612142080

Born to survive: how cancer cells resist CAR T cell therapy

Ejemplares similares